Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

<p>Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOX...

Saved in:

书目详细资料
主要作者:	Carlotta Antoniotti (15352506) (author)
其他作者:	Alessandra Boccaccino (15352509) (author), Robert Seitz (15352512) (author), Mirella Giordano (15352515) (author), Aurélie Catteau (15352518) (author), Daniele Rossini (15086287) (author), Filippo Pietrantonio (15035729) (author), Lisa Salvatore (15352521) (author), Kimberly McGregor (15352524) (author), Francesca Bergamo (15352527) (author), Veronica Conca (15352530) (author), Simone Leonetti (15352533) (author), Federica Morano (14937009) (author), Giorgio Papiani (15352536) (author), Emiliano Tamburini (15352539) (author), Maria Bensi (15352542) (author), Sabina Murgioni (15352545) (author), Douglas Teller Ross (15352548) (author), Alessandro Passardi (15352551) (author), Isabelle Boquet (15352554) (author), Tyler J. Nielsen (15352557) (author), Jérôme Galon (15031113) (author), Matthew Gordon Varga (15352560) (author), Brock L. Schweitzer (15352563) (author), Chiara Cremolini (15352566) (author)
出版:	2025
主题:	Cancer Tumor Biology Cancer Detection and Diagnosis Therapeutic Research and Development Immuno-oncology Biomarkers Gastrointestinal Cancers Colorectal cancer Immunotherapy Biomarkers for immunotherapy Translational Research Tumor Microenvironment Immune cells and the microenvironment
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
由: Sonia A. Patel (15055688)
出版: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
由: Sonia A. Patel (15055688)
出版: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
由: Sonia A. Patel (15055688)
出版: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
由: Sonia A. Patel (15055688)
出版: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
由: Sonia A. Patel (15055688)
出版: (2025)

Supplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated <i>SPP1</i><sup>+</sup> Macrophages and Fibroblasts
由: Anuja Sathe (15028097)
出版: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
由: Isha Mondal (16721699)
出版: (2025)

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
由: Aleksandar Obradovic (7549517)
出版: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
由: Aleksandar Obradovic (7549517)
出版: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
由: Daniel S. Green (15047598)
出版: (2025)

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
由: Francisco Hermida-Prado (14958909)
出版: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
由: Li-Li Long (14963775)
出版: (2025)

Table S2 from Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
由: Taohua Yue (14963045)
出版: (2025)

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
由: Andrew Nguyen (17142197)
出版: (2025)

Supplementary Figure S1 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
由: Anita L. Ray (15313398)
出版: (2025)

Supplementary Figure S2 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
由: Anita L. Ray (15313398)
出版: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_23a9h1ktvuufcru2idnbcdbuoe